Related Experiment Video
Updated: Feb 6, 2026

Culture of Bladder Cancer Organoids as Precision Medicine Tools
Published on: December 28, 2021
Long non-coding RNAs: new frontiers for advancing personalized cancer medicine in prostate cancer
Alireza Fotouhi Ghiam1,2, Danny Vesprini1,2, Stanley K Liu1,2,3
1Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Canada.
Abstract:
Long non-coding RNAs (lncRNAs) are a group of non-coding transcripts of more than 200 nucleotides that play important biological and clinical roles in prostate cancer (PCa) tumorigenesis, progression and metastasis. They have also shown potential as a biomarker in the diagnosis and prognosis of this disease. LncRNA prostate cancer associated transcript-14 (PCAT-14) was recently identified as a novel prognostic biomarker in PCa, whose low expression was associated with poor outcomes. Here, we briefly discuss future perspectives and clinical applications of lncRNAs as biomarkers and therapeutic targets for PCa.
Related Concept Videos
Cancer
lncRNA - Long Non-coding RNAs
lncRNA - Long Non-coding RNAs
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
piRNA - Piwi-interacting RNAs

